ALMS Latest Press Releases

-- October 9, 2026 --

Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures Globe Newswire 4:00 AM

-- September 4, 2026 --

Alumis to Participate in Upcoming September Investor Conferences Globe Newswire 8:00 AM

-- September 1, 2026 --

Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE) Globe Newswire 7:30 AM

-- August 13, 2026 --

Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements Globe Newswire 4:01 PM

-- August 10, 2026 --

Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies Globe Newswire 4:05 PM

-- May 14, 2026 --

Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements Globe Newswire 4:05 PM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software